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Abstract
Serotypes causing invasive pneumococcal disease (IPD) in children aged <2 years in Catalonia (Spain) before and after licensing of the
7-valent pneumococcal conjugated vaccine (7vPCV) were assessed, using samples taken during 1997–1999 and 2005–2007 respectively.
The distribution of serotypes causing IPD within these groups was obtained by serotyping strains sent by 22 Catalan hospitals to the
Carlos III Health Institute, Madrid. Between 1997–99 and 2005–2007, the proportion of vaccine serotypes causing IPD in Catalonia fell
from 70.54% to 31.67% (p <0.0001). The proportion of vaccine-related serotypes, mainly serotype 19A, increased from 9.82% to 32.50%
(p <0.0001). The proportion of non-vaccine, non-related serotypes (serotypes not related to vaccine serotypes) rose from 19.64% to
35.83% (p <0.05). Within this group, the proportions of serotype 24F increased signiﬁcantly. There has been a change in the distribution
of serotypes isolated from cases of IPD in children <2 years old in Catalonia, comprising a reduction in the proportion of 7-valent vaccine
serotypes, a rise in vaccine-related serotypes, especially 19A, and a smaller rise in non-vaccine, non-related serotypes, especially serotype
24F. A new 13-valent vaccine will cover 77.91% of the serotypes causing IPD in children <2 years old in Catalonia from 2005 to 2007.
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Introduction
The 7-valent pneumococcal conjugated vaccine (7vPCV) was
licensed in Spain in 2001 [1] and, although not yet incorpo-
rated into the routine vaccination schedule, except in the
Community of Madrid, its use has been recommended by
the Spanish Association of Paediatrics [2] and by many
private paediatric ofﬁces. In Catalonia in 2003, a telephone
survey investigating vaccination coverage in children aged
2 years, born in October 2001, revealed a 7vPCV vaccination
coverage of approximately 35% [3].
The 7vPCVserotypes (4, 6B, 9V, 14, 18C, 19F and 23F)
caused 82.2% of the cases of invasive pneumococcal disease
(IPD) in children in the USA in the 1990s [4]. In Spain, before
introduction of the 7vPCV, the proportion of vaccine sero-
types causing IPD in children aged <2 years was 68.2% [5].
The objective of this study was to analyse the evolution of
the distribution of serotypes causing IPD in children aged
<2 years in Catalonia before and after licensing of the 7vPCV,
between 1997–1999 and 2005–2007, respectively.
Materials and Methods
All serotypes isolated from children aged <2 years in the
periods 1997–1999 and 2005–2007 at 22 hospitals of Catalo-
nia and sent for serotyping to the Pneumococcal Reference
Laboratory, Carlos III Health Institute, Madrid, Spain, were
included in the study.
Serotyping was carried out using the Quellung reaction
calibrated according to international standards. Serotypes
were classiﬁed in accordance with the Danish nomenclature
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[5], and divided into three groups: serotypes included in the
vaccine (vaccine serotypes); serotypes belonging to the same
serogroup as vaccine serotypes (vaccine-related serotypes);
and serotypes not related to vaccine serotypes (non-vaccine,
non-related serotypes).
The v2 test was used to determine differences between
proportions, with a value of p <0.05 considered as statisti-
cally signiﬁcant [6]. The SPSS v12 program (SPSS Inc.,
Chicago, IL, USA) was used for the statistical analysis.
Results
During 1997–1999, 112 pneumococcal strains were sent to
the Carlos III Health Institute, of which the disease-causing
serotype was identiﬁed in 111 (99.11%). The most frequent
serotypes were 6B (16.96%), 14 (16.07%), 19F (15.18%), 18C
(7.14%) and 4 (6.25%), all of which are vaccine serotypes.
During 2005–2007, 240 strains were sent and the sero-
type was identiﬁed in 238 (99.17%). The most frequent sero-
types were vaccine-related serotype19A (22.08%), vaccine
serotype 14 (14.58%), vaccine-related serotype 6A (7.08%),
vaccine serotype 19F (6.25%) and non-vaccine, non-related
serotypes 7F (5.83%) and 5 (5.0%) (Table 1).
Between 1997–1999 and 2005–2007, the proportion of
vaccine serotypes in children aged <2 years fell from 70.54%
to 31.67% (p <0.05) and the proportion of vaccine-related
serotypes increased from 9.82% to 32.50% (p <0.0001).
Non-vaccine, non-related serotypes increased from 19.64%
to 35.83% (p <0.05) (Table 1).
Serotypes whose proportion increased signiﬁcantly were
vaccine-related 19A and non-vaccine, non-related 24F
(Table 1). The proportion of vaccine serotypes 4, 6B, 18C
and 19F fell signiﬁcantly (Table 1).
The serotypes included in the future 10-valent vaccine
(the seven serotypes included in the 7vPCV plus serotypes
1, 5 and 7F) represented 81.25% and 46.67% of serotypes
causing IPD in children aged <2 years in Catalonia in 1997–
1999 and 2005–2007, respectively (Table 2). Serotypes
included in the future 13-valent vaccine (the above serotypes
plus serotypes 3, 6A and 19A) represented 90.18% and
77.92%, respectively (Table 2).
Discussion
Since the licensing of the 7vPCV, there has been expectation
that the ecological niche left by vaccine serotypes could be
occupied by non-vaccine serotypes, leading to the emergence
of serotypes not included in the vaccine [7].
Routine administration of the 7vPCV in the USA in chil-
dren aged <2 years has provided substantial health beneﬁts,
both direct (reduced incidence of IPD caused by vaccine ser-
otypes, and a reduced proportion of antibiotic-resistant ser-
otypes) [8–11] and indirect (reduced prevalence of vaccine
serotype carriers, and reduced incidence of IPD in unvacci-
nated children and elderly people, all due to the effect of
herd immunity) [12–17]. The possible negative effects of vac-
cination (such as the emergence of non-vaccine serotypes in
both carriers and cases) have also been widely studied in the
USA [18–23] and the latest data indicate that, 5 years after
the introduction of routine vaccination, the magnitude of
emergence is very small compared with the beneﬁts of
vaccination [21,24,25]. The incidence of IPD cases caused by
vaccine serotypes has fallen by 97%, whereas cases due to
non-vaccine, non-related serotypes have increased by only
TABLE 1. Serotypes causing invasive pneumococcal disease
in children aged <2 years in Catalonia (Spain) before and
after licensing of the 7-valent pneumococcal conjugate
vaccine (1997–1999 and 2005–2007, respectively)
1997–1999 2005–2007
pAbsolute % Absolute %
Vaccine serotypes
4 7 6.25 3 1.25 <0.05
6B 19 16.96 9 3.75 0.0002
9V 5 4.46 4 1.67 NS
14 18 16.07 35 14.58 NS
18C 8 7.14 5 2.08 <0.05
19F 17 15.18 15 6.25 <0.05
23F 5 4.46 5 2.08 NS
Total 79 70.54 76 31.67 <0.05
Vaccine-related serotypes
6A* 5 4.46 17 7.08 NS
9N 1 0.89 2 0.83 NS
19A 4 3.57 53 22.08 <0.0001
23B 1 0.89 6 2.50 NS
Total 11 9.82 78 32.50 <0.0001
Non-vaccine, non-related serotypes
1 4 3.57 10 4.17 NS
3 1 0.89 5 2.08 NS
5 5 4.46 12 5.8 NS
7F 3 2.68 14 5.83 NS
8 0 0 1 0.42 NS
10A 1 0.89 6 2.50 NS
12F 0 0 7 2.92 NS
15A 2 1.79 1 0.42 NS
15BC 1 0.89 5 2.08 NS
16F 0 0 1 0.42 NS
22F 2 1.79 1 0.42 NS
24F 0 0 11 4.58 <0.05
28F, 28A 0 0 1 0.42 NS
32F,32 A 1 0.89 0 0 NS
33 F 0 0 5 2.08 NS
35F 1 0.89 0 0 NS
35B 0 0 2 0.83 NS
38 0 0 2 0.83 NS
Not serotyped 1 0.89 2 0.83 NS
Total 22 19.64 86 35.83 <0.05
All serotypes 112 100 240 100
NS, not signiﬁcant.
*May be serotype 6C, at least in part; the classic methods of serotyping (Quel-
lung reaction) cannot distinguish between serotype A and serotype C.
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20% [24,25]. Therefore, in the USA, current expert consen-
sus is that the direct and indirect beneﬁts of routine paediat-
ric administration of the 7vPCV have greatly exceeded the
possible negative effects [26–28]. Vaccination coverage in the
USA has been very high and the distribution of vaccination
quite uniform, with only small differences according to social
class [10,12,27]. Therefore, if vaccination coverage is high,
the beneﬁts of vaccination are only slightly eroded by the
possible negative impact of the increase in non-vaccine sero-
types [27,29,30].
However, the effects of individual 7vPCV administration in
private paediatric ofﬁces, which results in a less uniform
demographic distribution of vaccination, with better coverage
in higher social classes, as applies in Catalonia, have been lit-
tle studied.
Our study shows a reduction in the proportion of vaccine
serotypes and an increase in the proportion of vaccine-
related and non-vaccine, non-related serotypes in Catalonia
in children aged <2 years with IPD after introduction of the
7vPCV. The increase in vaccine-related serotype 6A may be
due, at least in part, to the increase in the newly discovered
serotype 6C [31]. The classic Quellung reaction cannot dis-
tinguish between serotypes 6A and 6C [31]. Most, but not
all, studies have found that the 7vPCV provides cross-protec-
tion against serotype 6A but not against 6C [32]. In the
USA, introduction of the 7vPCV has led to a reduction in
serotype 6A but not in serotype 6C [32].
Our results are similar to those observed in the whole of
Spain by the Pneumococcal Reference Centre, Carlos III
Health Institute, which serotypes all pneumococcal strains
sent by Spanish hospitals [33]. A similar pattern has been
noted in studies of different Spanish regions [34–38]. In
other reports, however, no relevant changes in serotype dis-
tribution after the introduction of the 7vPCV [39,40] have
been documented. A substantial increase in the incidence of
paediatric empyemata has also been observed, a high propor-
tion of which is caused by non-vaccine serogroup 1
[35,37,38].
In some of these studies incidence rates have been calcu-
lated, but in these studies data were drawn either from small
autonomous communities [34,39] or from poorly deﬁned
populations within an autonomous community [35,37,38].
The lack of data on the national incidence of IPD according
to serotype before and after licensing of the 7vPCV makes it
difﬁcult to analyse the replacement phenomenon in Spain.
The emergence and increase of some non-vaccine sero-
types, especially 19A, has coincided with the introduction of
the 7vPCV, leading to some reports suggesting that they are
related phenomena. However, the increase in new non-
vaccine serotypes can occur without introduction of the
7vPCV [27,29,30,41]. An example is South Korea, where
there was a substantial increase in the frequency of serotype
19A isolated from children aged <5 years before licensing of
the 7vPCV in 2004 (from 0% of isolates of serotypes of
Streptococcus pneumoniae during 1991–1994 to 8–10% during
1995–2000) [41]. Likewise, a recent study in Israeli Bedouins
found an increase of 68% in the proportion of cases of otitis
media caused by serotype 19A in the absence of 7vPCV
administration [42].
Two recent studies on routine 7vPCV vaccination in
Norway [43] and in Native-American reservations in New
Mexico [44] both found a dramatic reduction in the inci-
dence of cases caused by vaccine serotypes, with no replace-
ment, i.e. no corresponding increase in non-vaccine
serotypes. These results indicate that vaccination is not nec-
essarily accompanied by replacement of serotypes.
When vaccination already has a substantial impact on vac-
cine serotypes, the reasons for the replacement of vaccine
serotypes by some non-vaccine serotypes are not completely
clear [27,29,30].
Moore and colleagues [30,45] recently suggested that,
although the emergence of serotype 19A in the USA
occurred after the introduction of the 7vPCV, there is not
sufﬁcient evidence to implicate vaccination as the only causal
factor, or even to consider it as the most important
factor. They suggest that serotype 19A was far better posi-
tioned to occupy the ecological niche left by vaccine
serotypes than other non-vaccine serotypes. Unlike most
non-vaccine serotypes, 19A can cause the three forms of
interaction between the pneumococcus and the human host:
nasopharyngeal colonization, otitis media and IPD. Before
licensing of the 7vPCV, 19A was the ninth most important
TABLE 2. Serotypes causing inva-
sive pneumococcal disease in chil-
dren aged <2 years included in the
7-valent, 10-valent and 13-valent





D Accumulated D Accumulated
7-valent 4, 6B, 9V, 14, 18C, 19F, 23F – 70.54% – 31.67%
10-valent 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F +10.71% 81.25% +15.0% 46.67%
13-valent 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F +8.93% 90.18% +31.25% 77.92%
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serotype causing IPD in the USA in children aged <5 years,
only exceeded by the seven vaccine serotypes and by
serotype 6A. At that time, it was the main serotype causing
carrier state in the USA. In addition, c. 60% of cases of sero-
type 19A isolated in IPD and 25–75% of carriers identiﬁed
were resistant to penicillin. These results suggest that sero-
type 19A is more aggressive than other non-vaccine sero-
types. In addition, 7vPCV vaccination has been shown not to
be effective against serotype 19A according to the studies
carried out before introduction of the vaccine, which
showed no cross-immunity between vaccine serotype 19F
and serotype 19A [11,46,47].
Black has recently suggested that serotype replacement is
not due to vaccination, or at least that vaccination is not the
most important factor [48]. He suggests that the determin-
ing factor is the uncontrolled use of antibiotics, especially
macrolides, without speciﬁc indications for the treatment of
paediatric respiratory infections. In Native-American reser-
vations in Arizona, where azithromycin is approved only for
the treatment of sexually transmitted diseases and children
with documented allergy to penicillin, replacement has not
been observed after vaccination [44]. By contrast, among
indigenous Alaskans, substantial replacement of serotypes
was observed after vaccination [22], coinciding with wide-
spread use of azithromycin to treat pneumonia and otitis
media. Similarly, among Israeli Bedouins, the emergence of
serotype 19A coincided with mass use of azithromycin to
treat acute paediatric respiratory infections in the absence
of 7vPCV vaccination [42]. Black also suggested that the
emergence of vaccine serotypes in Barcelona observed by
Mun˜oz-Almagro et al. [37] would have occurred with rela-
tively low vaccination coverage (only 36% of children had
received one dose in 2005 and 47% in 2007), and that this
could have been due, at least in part, to mass, uncontrolled
use of antibiotics, especially macrolides, to treat mild paedi-
atric infections [48].
Like all epidemiological studies, our results may have been
subject to bias. One factor could be changes in the criteria
for sending strains of pneumococcus to the Carlos III Health
Institute for serotyping. For example, some hospitals did not
begin to send isolates in cases of empyemata until 2004,
which could have led to underestimation of the most fre-
quent serotypes in empyemata (serotype 1, for example)
during 1997–1999. However, the increase in the number of
strains sent (240 during 2005–2007 vs. 112 during 1997–
1999), probably due to increased interest in the disease by
paediatricians after licensing of the vaccine, does not seem
to have caused any bias.
Currently, a new 13-valent vaccine that includes serotypes
6A and 19A is under preparation [49]. Our results show that
this vaccine would cover 77.92% of current serotypes caus-
ing IPD in children aged <2 years in Catalonia and therefore
would be a welcome addition.
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